Skip to main content

tafasitamab

Generic: tafasitamab·Brand: Monjuvi

tafasitamab: 27 clinical trials tracked.

tafasitamab evidence translation

What we can confirm

27 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tafasitamab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence7 indications · 4 study sponsors
Clinical Trials (27)showing 10 most recent

TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma

NCT07731789·Phase 2
Not yet recruiting

Primary endpoint: Complete remission at the best response

Interventionalopen30 targetStarted 2026-10Completion 2032-101 site · United StatesUniversity of Washington

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

NCT07225439·Phase 1
Not yet recruiting

Primary endpoint: Dose limiting toxicity (DLT)

Interventionalopen15 targetStarted 2026-09Completion 2027-122 sites · United StatesPaolo Caimi, MD

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

NCT07502872·Phase 2
Not yet recruiting

Primary endpoint: Complete response rate

Interventionalopen30 targetStarted 2026-05Completion 2029-121 site · United StatesBrown University

Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)

NCT07030699·Phase 2
Withdrawn

Primary endpoint: best complete response rate (CRR)

Interventionalopen0 targetStarted 2025-08Completion 2026-03Memorial Sloan Kettering Cancer Center

HM2023-43: A Phase 2 Trial of Tafasitamab in Combination With Lenalidomide+Rituximab in Treatment-naive Follicular Lymphoma and Marginal Zone Lymphoma

NCT06792825·Phase 2
Recruiting

Primary endpoint: Complete response (CR)

Interventionalopen65 targetStarted 2025-08Completion 2031-071 site · United StatesMasonic Cancer Center, University of Minnesota

Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma After Axicabtagene Ciloleucel

NCT06760156·Phase 2
Recruiting

Primary endpoint: Complete Response Rate (CRR)

Interventionalopen28 targetStarted 2025-03Completion 2028-011 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)

NCT05583071·Phase 2
Recruiting

Primary endpoint: complete response rate (CRR)

Interventionalopen20 targetStarted 2024-08Completion 2027-046 sites · GermanyUniversity of Cologne

A Phase 1/2 Study of Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

NCT06029309·Phase 1/Phase 2
Recruiting

Primary endpoint: Phase 1: Recommended Phase 2 Dose (RP2D) of Zanubrutinib

Interventionalopen27 targetStarted 2024-05Completion 2032-051 site · United StatesAlvaro Alencar, MD

A Phase Ib Study Evaluating the Safety and Efficacy of Tafasitamab, Acalabrutinib, and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT05943496·Phase 1
Recruiting

Primary endpoint: Incidence of dose limiting toxicities (DLTs)

Interventionalopen27 targetStarted 2023-10Completion 2028-011 site · United StatesOHSU Knight Cancer Institute

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

NCT05890352·Phase 2
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedopen227 targetStarted 2023-09Completion 2029-0150 sites · United StatesSWOG Cancer Research Network